Antibodies for the treatment of brain metastases, a dream or a reality?

Detalhes bibliográficos
Autor(a) principal: Cavaco, Marco
Data de Publicação: 2020
Outros Autores: Gaspar, Diana, Castanho, Miguel A. R. B., Neves, Vera
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10451/49569
Resumo: © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
id RCAP_e4d824e5bf149bb2fe64eff30e233aa5
oai_identifier_str oai:repositorio.ul.pt:10451/49569
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Antibodies for the treatment of brain metastases, a dream or a reality?Adsorptive-mediated transcytosisAntibody fragmentsBlood–brain barrierBrain metastasesMonoclonal antibodiesPeptide shuttles© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).The incidence of brain metastases (BM) in cancer patients is increasing. After diagnosis, overall survival (OS) is poor, elicited by the lack of an effective treatment. Monoclonal antibody (mAb)-based therapy has achieved remarkable success in treating both hematologic and non-central-nervous system (CNS) tumors due to their inherent targeting specificity. However, the use of mAbs in the treatment of CNS tumors is restricted by the blood-brain barrier (BBB) that hinders the delivery of either small-molecules drugs (sMDs) or therapeutic proteins (TPs). To overcome this limitation, active research is focused on the development of strategies to deliver TPs and increase their concentration in the brain. Yet, their molecular weight and hydrophilic nature turn this task into a challenge. The use of BBB peptide shuttles is an elegant strategy. They explore either receptor-mediated transcytosis (RMT) or adsorptive-mediated transcytosis (AMT) to cross the BBB. The latter is preferable since it avoids enzymatic degradation, receptor saturation, and competition with natural receptor substrates, which reduces adverse events. Therefore, the combination of mAbs properties (e.g., selectivity and long half-life) with BBB peptide shuttles (e.g., BBB translocation and delivery into the brain) turns the therapeutic conjugate in a valid approach to safely overcome the BBB and efficiently eliminate metastatic brain cells.This research was funded by the Portuguese Funding Agency, Fundação para a Ciência e Tecnologia, FCT IP, grants PD/BD/128281/2017, PTDC/BBB-BQB/1693/2014 and PTDC/BBB-NAN/1578/2014.MDPIRepositório da Universidade de LisboaCavaco, MarcoGaspar, DianaCastanho, Miguel A. R. B.Neves, Vera2021-09-21T15:59:56Z20202020-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10451/49569engPharmaceutics. 2020 Jan 13;12(1):6210.3390/pharmaceutics120100621999-4923info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-08T16:53:28Zoai:repositorio.ul.pt:10451/49569Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T22:01:12.008849Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Antibodies for the treatment of brain metastases, a dream or a reality?
title Antibodies for the treatment of brain metastases, a dream or a reality?
spellingShingle Antibodies for the treatment of brain metastases, a dream or a reality?
Cavaco, Marco
Adsorptive-mediated transcytosis
Antibody fragments
Blood–brain barrier
Brain metastases
Monoclonal antibodies
Peptide shuttles
title_short Antibodies for the treatment of brain metastases, a dream or a reality?
title_full Antibodies for the treatment of brain metastases, a dream or a reality?
title_fullStr Antibodies for the treatment of brain metastases, a dream or a reality?
title_full_unstemmed Antibodies for the treatment of brain metastases, a dream or a reality?
title_sort Antibodies for the treatment of brain metastases, a dream or a reality?
author Cavaco, Marco
author_facet Cavaco, Marco
Gaspar, Diana
Castanho, Miguel A. R. B.
Neves, Vera
author_role author
author2 Gaspar, Diana
Castanho, Miguel A. R. B.
Neves, Vera
author2_role author
author
author
dc.contributor.none.fl_str_mv Repositório da Universidade de Lisboa
dc.contributor.author.fl_str_mv Cavaco, Marco
Gaspar, Diana
Castanho, Miguel A. R. B.
Neves, Vera
dc.subject.por.fl_str_mv Adsorptive-mediated transcytosis
Antibody fragments
Blood–brain barrier
Brain metastases
Monoclonal antibodies
Peptide shuttles
topic Adsorptive-mediated transcytosis
Antibody fragments
Blood–brain barrier
Brain metastases
Monoclonal antibodies
Peptide shuttles
description © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
publishDate 2020
dc.date.none.fl_str_mv 2020
2020-01-01T00:00:00Z
2021-09-21T15:59:56Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10451/49569
url http://hdl.handle.net/10451/49569
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Pharmaceutics. 2020 Jan 13;12(1):62
10.3390/pharmaceutics12010062
1999-4923
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799134559957155840

Registros relacionados